Biotech Company Nuritas Hires New Chief Medical & Innovation Officer 

Nuritas, the global leader in Artificial Intelligence-based peptide discovery, has appointed Dr. Andy Franklyn-Miller as its Chief Medical and Innovation Officer.  

With a wealth of knowledge in physiology, clinical design and translating science to consumers, Dr. Franklyn-Miller brings decades of medical expertise to the Nuritas team. He joins Nuritas after having overseen the second clinical trial of the intelligent ingredient PeptiStrong™ in collaboration with the Nuritas Teams.  

‘As a physician, it is at times frustrating that you can only influence the lives of the patient in front of you. After working with Nuritas on the clinical for Peptistrong and seeing the potential of the biological catalyst of natural peptides across multiple modes of action, it was impossible to turn down the opportunity to join such a pioneering team. We only need to look at the huge challenges in the world of cardiovascular, metabolic, neurocognitive health and inflammation to see how we can positively affect the health and longevity of billions.’ 

Dr. Franklyn-Miller graduated from Imperial College London and holds a Ph.D. in Biomechanics from University of Roehampton. For 16 years he served in the Royal Navy and Royal Marines as a physician across various roles worldwide, before developing a commercial research and clinical practice that has grown to become the largest in Europe.  

Throughout his impressive career, Dr. Franklyn-Miller has worked both with many high-profile sports teams and elite performers but has also managed research teams and commercial 3D biomechanics and physiological testing facilities. He is an editor of the British Journal of Sports Medicine, author of the textbook Clinical Sports Anatomy and of the IOC Handbook of Sports Injuries, and he has published more than 60 peer-reviewed papers. 

His experience in machine learning, clinical trials and end user analysis has allowed him to build successful data systems and models and brings a unique blend of commercial research and innovation alongside leadership and management.  

“Andy brings with him such a tremendous set of skills and expertise within his extensive background in physiology and clinical design, expertise that we saw in action when he worked with Nuritas on the second clinical trial for our muscle ingredient PeptiStrong™. His impressive career in both medicine and commercial research, combined with his experience in machine learning make him the perfect fit to lead teams in multiple departments. We look forward to the innovation and growth that Dr. Franklyn-Miller’s leadership will bring to Nuritas”, commented Dr Nora Khaldi, CEO and Founder. 

“As Nuritas continues to innovate and expand, Dr. Franklyn-Miller’s experience will be invaluable as he oversees our magnifier technology and its translation into human clinicals.” 

About Nuritas   

What if the future of intelligent ingredients was here but remained hidden away from science? Through pioneering life science and artificial intelligence, Nuritas and our unique Nuritas MagnifierNπΦ allows us to identify, unlock, clinically test, and patent peptides; turning them into powerful and precise ingredients that elevate natural efficacy. We want to empower people to live healthier lives, naturally by making our everyday products healthier, safer, greener, and more efficacious – from what we eat, to what we apply to our skin, all the way to what we feed our livestock. By translating nature’s wisdom into innovation, together, we can change the life of billions. Find us on TwitterLinkedIn or via our website at    

The Editorial Team at Healthcare Business Today is made up of skilled healthcare writers and experts, led by our managing editor, Daniel Casciato, who has over 25 years of experience in healthcare writing. Since 1998, we have produced compelling and informative content for numerous publications, establishing ourselves as a trusted resource for health and wellness information. We offer readers access to fresh health, medicine, science, and technology developments and the latest in patient news, emphasizing how these developments affect our lives.